Full Press Release Details
MINNEAPOLIS , March 1, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate (EPI) test for men. Humana is the nation's largest Medicare Advantage provider serving an estimated 20 million patients in the United States .
About Bio-Techne Corporation (NASDAQ: TECH )
ExosomeDx a Bio-Techne Brand
Contact: David Clair , Senior Director, Investor Relations and Business Development
[email protected]
SOURCE Bio-Techne Corporation